Alcon has bought rights for and Zirgan from Sirion Therapeutics Inc. for an undisclosed amount. While Durezol is an ophthalmic corticosteroid approved for the treatment of inflammation and pain associated with eye surgery, Zirgan is an antiviral for the treatment of corneal ulcers. Both products have been approved by the Food and Drug Administration.

Alcon said it has acquired the global rights, excluding Latin America, for Zyclorin, which is being developed as a potential treatment for dry eyes and other diseases.

Alcon has announced that it will purchase the rights in the United States for two FDA-approved topical eye care products from Sirion Therapeutics, Inc. The two products purchased are Durezol™, a marketed ophthalmic corticosteroid approved for the treatment of inflammation and pain associated with eye surgery, and Zirgan™, a recently approved antiviral for the treatment of acute herpetic keratitis (corneal ulcers).

For the full story, Click Here

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on recommendation for approval to grant a marketing authorisation for Alcon Laboratories’ Azarga 10 mg/ml / 5 mg/ml Eye drops. The suspension will be a more effective treatment of elevated intraocular pressure for adult patients suffering from ocular hypertension or open-angle glaucoma who have not benefited much from mono-therapy.The drug is a fixed combination of Timolol and Brinzolamide. These compounds reduce the production of aqueous humor by inhibiting the conversion of CO2 to bicarbonate in the eye’s ciliary body, hence controlling IOP.